Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Approval Alert: Biocon Receives First UK Approval of Liraglutide Biosimilar

Mar 27, 2024

On 27 March 2024, Biocon announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) approved its liraglutide in the UK, which is the first approved biosimilar to Novo Nordisk’s Victoza® (liraglutide).  Biocon’s liraglutide, a drug-device combination (6mg/ml solution for injection in pre-filled pen) used to treat Type 2 Diabetes, was filed and will be marketed in the UK by its European partner, Zentiva.

This follows the Indian launch of a liraglutide biosimilar, Glenmark’s Lirafit®, in January this year.